We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective, randomized study comparing quinupristindalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
- Authors
Issam Raad; Ray Hachem; Hend Hanna; Claude Afif; Carmen Escalante; Hagop Kantarjian; Kenneth Rolston
- Abstract
Objectives: Quinupristindalfopristin and linezolid have been shown to be efficacious in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections. However, the two antibiotics have not been compared in terms of safety and efficacy in a prospective randomized study. The objective of this study was to compare the safety and efficacy of the two drugs in the treatment of VREF infections in cancer patients.Patients and methods: Forty cancer patients with VREF infection were randomized to receive linezolid 600 mg every 12 h or quinupristindalfopristin 7.5 mg/kg every 8 h. All patients were followed up for 30 days after discontinuation of study drugs.Results: Linezolid and quinupristindalfopristin had comparable clinical responses (58% and 43%, respectively, P = 0.6). Myalgias and/or arthralgias occurred at a frequency of 33% in patients who received quinupristindalfopristin, but were not observed in the linezolid group (P = 0.03). In contrast, drug-related thrombocytopenia occurred in 11% of patients who received linezolid, but was not observed in the quinupristindalfopristin group (P = 0.2).Conclusion: In cancer patients, quinupristindalfopristin treatment is associated with a relatively high frequency of myalgias/arthralgias; however, profound thrombocytopenia might limit the choice of linezolid in a subpopulation of cancer patients.
- Subjects
GLYCOPEPTIDE antibiotics; STREPTOCOCCACEAE; THROMBOCYTOPENIA; ANTI-infective agents
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2004, Vol 53, Issue 4, p646
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkh144